What about BPC-157 and TB-500?

Retatrutide at least has large human trials underway. Two other peptides you’ll hear about, BPC-157 and TB-500, are further from that finish line than most people realize. It’s worth being specific about why.

Online, BPC-157 gets described as a near-miraculous healing peptide for tendons, gut, and joints. There’s a large body of animal research behind it, well over a hundred studies in rats and mice showing interesting effects. But animal data isn’t human proof.

A 2025 systematic review in orthopaedic sports medicine set out to find the human evidence. Out of 544 articles screened, only 36 met the bar, and 35 of those were preclinical (animal or lab studies). That left a single human study: a retrospective look at 12 people who received a BPC-157 injection into the knee for chronic pain, 7 of whom reported relief lasting more than six months. The authors graded the overall evidence as Level 4 and Level 5, the lowest tiers, and found no human safety data at all. As of 2026, no published randomized controlled trial has shown BPC-157 is effective or safe in humans for any condition, and it isn’t approved for human use by any regulator in the world.

TB-500 carries a subtler trap. It’s marketed as interchangeable with thymosin beta-4, a natural protein that has been studied in some early human safety trials. But TB-500 is a synthetic fragment, and no dedicated human trials have established that TB-500 itself is safe or effective.

To be fair, an evidence gap isn’t proof that something doesn’t work. These peptides might earn real human evidence someday. But right now, when companies say “the studies are promising,” what they mean is that the animal studies are promising. And that’s a huge gap. You’re not a lab rat. You’re a person taking a peptide from an unverified vial at a dose nobody’s actually tested in humans. That’s a leap we would never ask a patient to make on faith alone.

Often, the bigger question is the source, not the science.

There’s a second issue that gets less attention than the compounds themselves, and it’s worth understanding.

Because Retatrutide isn’t legally available outside registered clinical trials, the versions circulating online come from an unregulated secondary market, often labelled “research use only.” A medication dispensed by a pharmacy has passed verified quality control: you know what’s in it, at what concentration, where it was made, and who’s monitoring it. A gray-market vial gives you none of that. Independent lab tests on these peptides have found all kinds of problems:

• Contamination with bacteria or unknown substances
• Far more or far less of the active ingredient than the label claims
• In some cases, completely different compounds than what’s supposed to be in the vial

Set the peptide debate aside for a moment and the concern gets simple: you’d be injecting something without knowing where it actually came from. Regulators have started to respond. In one recent U.S. case, a physician was federally indicted for importing unapproved peptides and giving them to patients, and some medical boards have moved to prohibit “research-grade” peptide prescribing.

Three questions to ask before trying any new therapy; Not just peptides, but anything:

1. Is it approved by Health Canada, or still investigational?
2. Where does it physically come from, and who verifies its quality?
3. Who is monitoring me (my labs, my body composition, my response) while I take it?

If any answer is “I’m not sure,” that’s your signal to slow down.